Cargando…

Efficacy and Safety Results of the Afatinib Expanded Access Program

INTRODUCTION: Afatinib is an oral, irreversible ErbB family blocker approved for first-line treatment of metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer (NSCLC). The expanded access program (EAP) allowed early access to afatinib and provided additional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Edward S., Halmos, Balazs, Kohut, Ingrid F., Patel, Taral, Rostorfer, Regan D., Spira, Alexander I., Cseh, Agnieszka, McKay, John, Wallenstein, Gudrun, Mileham, Kathryn F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488108/ https://www.ncbi.nlm.nih.gov/pubmed/28680960 http://dx.doi.org/10.1007/s40487-017-0043-5

Ejemplares similares

Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
por: Wiebe, Sabrina, et al.
Publicado: (2016)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Genomic Analysis of Tumors from Patients with Glioblastoma with Long-Term Response to Afatinib
por: Owen, Scott, et al.
Publicado: (2022)

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report
por: Alshami, Jad, et al.
Publicado: (2015)

Accessing an Expanded Exposure Science Module at the Comparative Toxicogenomics Database
por: Grondin, Cynthia J., et al.
Publicado: (2018)

Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial
por: Saran, Frank, et al.
Publicado: (2021)

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
por: Lu, Shun, et al.
Publicado: (2018)

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
por: Thongprasert, Sumitra, et al.
Publicado: (2019)

OME-NGFF: a next-generation file format for expanding bioimaging data-access strategies
por: Moore, Josh, et al.
Publicado: (2021)

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
por: Hochmair, Maximilian J., et al.
Publicado: (2018)

Medical Student Documentation in the Electronic Medical Record: Patterns of Use and Barriers
por: Wittels, Kathleen, et al.
Publicado: (2017)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
por: Zhang, Li, et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

Expanding access to microneurosurgery in low-resource settings: Feasibility of a low-cost exoscope in transforaminal lumbar interbody fusion
por: Ramirez, Manuel Encarnacion, et al.
Publicado: (2023)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
por: Park, Keunchil, et al.
Publicado: (2021)

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial
por: Goss, Glenwood D, et al.
Publicado: (2021)

Unlocking the potential: Expanding plastid transformation for beyond-organelle function
por: Liu, Peng
Publicado: (2023)

Cardiac safety of afatinib: a review of data from clinical trials
por: Ewer, Michael S., et al.
Publicado: (2015)

Expanding the Functionality of an Autoinduction Device for Repression of Gene Expression in Bacillus subtilis
por: Silva, Bruna F., et al.
Publicado: (2022)

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
por: Kim, Minhye, et al.
Publicado: (2021)

Afatinib in Non–Small Cell Lung Cancer
por: Wirth, Scott M.
Publicado: (2015)

Chinese Medicine Treatment for Afatinib-Induced Paronychia
por: Yang, Pei-Yuu, et al.
Publicado: (2017)

Afatinib use in recurrent epithelial ovarian carcinoma
por: Shepherd-Littlejohn, Amanda L., et al.
Publicado: (2019)

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
por: Schuler, M., et al.
Publicado: (2016)

Geographic Access to Diabetes Prevention Program Sites: New York State Department of Health
por: Ruberto, Rachael A., et al.
Publicado: (2014)

User-centered design of central venous access device documentation
por: Kandaswamy, Swaminathan, et al.
Publicado: (2022)

Expanding access to COVID-19 testing, vaccination and treatment at a free clinic for uninsured Spanish-speaking adults in Providence, RI
por: Barry, Katherine, et al.
Publicado: (2022)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

No obvious effect on mortality from a patient choice reform expanding access to opioid disorder treatment – results from a natural experiment of policy change in Sweden
por: Håkansson, Anders, et al.
Publicado: (2023)

The sound of swearing: Are there universal patterns in profanity?
por: Lev-Ari, Shiri, et al.
Publicado: (2022)

Expanding access to HIV prevention
por: Gayle, Helene D
Publicado: (2006)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Afatinib in advanced NSCLC: a profile of its use
por: Deeks, Emma D., et al.
Publicado: (2018)

First reported case of afatinib‐associated toxic megacolon
por: Kwok, Wang Chun, et al.
Publicado: (2018)

Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
por: Nakamura, Tomomi, et al.
Publicado: (2018)

The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review
por: Heinzerling, John H., et al.
Publicado: (2021)

A Telemedicine Buprenorphine Clinic to Serve New York City: Initial Evaluation of the NYC Public Hospital System's Initiative to Expand Treatment Access During the COVID-19 Pandemic
por: Tofighi, Babak, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vhv2dj9bd4v1nctn8gg4ujfqgi